Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
LLY : 767.76 (+1.35%)
ONC.TO : 1.19 (-9.16%)
OSTX : 3.97 (+1.53%)
CRDF : 4.26 (-5.12%)
Cardiff Oncology Reports Promising Initial Results from Phase 2 CRDF-004 Trial of Onvansertib in RAS-Mutated mCRC

Cardiff Oncology's Phase 2 trial shows onvansertib combined with SoC yields 64% ORR in RAS-mut mCRC patients.Quiver AI SummaryCardiff Oncology, Inc. announced positive preliminary results from its Phase...

CRDF : 4.26 (-5.12%)
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

CRDF : 4.26 (-5.12%)
Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 4.26 (-5.12%)
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

CRDF : 4.26 (-5.12%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar